SNN
Smith & Nephew PLC
$30.32
▲ 0.2%Updated Today 12:11 PM ET
SNN at a glance — five pillars scored 0–100 from real filed financials.
Overall: Neutral · 56/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▲ Up 0.3% over the last 12 months
Market Cap
$12.09B
P/E
20.32x
Forward P/E (est.)
14.51x
ROE
11.6%
Revenue Growth
6.1%
EPS Growth
52.3%
Profit Margin
10.1%
FCF Yield
2.5%
Debt / Equity
0.63x
ROIC
—
Interest Coverage
—
Current Ratio
—
Dividend Yield
2.6%
Implied Growth (rev. DCF)
—
Rating Score
56/100
Smith & Nephew PLC (SNN) is a large-cap company in the Health Care industry, part of the Health Care sector of the S&P 500, with a market value around $12.09B.
Our model rates SNN Neutral (56/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what SNN's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. SNN trades near $30.32, below its 50-day average ($30.33) and 200-day average ($33.22). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 48 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. SNN's is $0.70 (~2.3% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month SNN found buyers near $28.56 (support) and sellers near $31.40 (resistance); its 52-week range is $28.56–$38.79. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.5× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
The case for SNN:
- Pays a 2.6% dividend on top of any price gains.
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against SNN:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Smith & Nephew PLC is a large-cap health care business growing at a mature pace, with modest profitability, and a sound balance sheet. It trades at 20.3x earnings, which our model scores Neutral (56/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
SNN — frequently asked questions
Is SNN a good stock to buy?
We don't give buy or sell advice. Our model rates Smith & Nephew PLC Neutral (56/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is SNN's rating on The Stocks School?
Smith & Nephew PLC currently scores 56/100 (Neutral) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does SNN's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Smith & Nephew PLC's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for SNN calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this SNN analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell SNN. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.